Abstract
Galanin is a highly inducible neuropeptide, showing distinct up-regulation after pathological disturbance within the nervous system. Significant increase in galanin expression is observed after peripheral nerve injury, in the basal forebrain in Alzheimer’s disease (AD), during neuronal development, and after stimulation with estrogen, while seizure activity deplete galanin in the hippocampus. A wide distribution of galanin and its receptors is seen in the nervous system, often in co-localization with classical neurotransmitters and other neuromodulators. Galanin acts predominantly as an inhibitory, hyperpolarizing neuromodulator on neurotransmitter and glucose-induced insulin release and stimulates growth hormone and prolactin secretion. Galanin has been implicated in several higher order physiological functions including cognition, feeding, nociception, mood regulation, and neuroendocrine modulation. The effects of galanin are mediated via three G protein-coupled receptors with different functional coupling. Moderate to low pharmacological effects are seen by galanin under physiological conditions, in contrast to its dramatic effects on the nervous system after neuronal disturbance. This pathophysiological heavy function of the galaninergic system renders it an interest for disorders such as AD, depression, and epilepsy in terms of side effects. Some properties of the galaninergic system are of particular importance in the context of neurodegeneration. Galanin is highly inducible, 10- to 100-fold, upon nerve injury, whereas most neuropeptides are induced 1.5- to 2-fold. Galanin is strongly neurotrophic during development as well as subsequent to injury. Whereas other neurotrophic neuropeptides like VIP and PACAP activate cAMP synthesis, galanin suppresses its synthesis, yet it is a strong neurotrophic as well as neuroprotective agent. As we delineate which galanin receptor subtype mediates neuroprotective and neurotrophic effects and which mediates synaptic inhibition, pharmacological use of receptor-selective galaninergic ligands for treatment in neurodegenerative diseases are coming closer.
Similar content being viewed by others
References
Ahrén B., Arkhammar P., Berggren P. O., and Nilsson T. (1986) Galanin inhibits glucose-stimulated insulin release by a mechanism involving hyperpolarization and lowering of cytoplasmic free Ca2+ concentration. Biochem. Biophys. Res. Commun. 140, 1059–1063.
Ahrén B., Pacini G., Wynick D., Wierup N., and Sundler F. (2004) Loss-of-function mutation of the galanin gene is associated with perturbed islet function in mice. Endocrinology 145, 3190–3196.
Amoroso D., Girotti P., Fisone G., Bartfai T., and Consolo S. (1992) Mechanism of the galanin induced increase in acetylcholine release in vivo from striata of freely moving rats. Brain Res. 589, 33–38.
Anisimov S. V., Tarasov K. V., Riordon D., Wobus A. M., and Boheler K. R. (2002a) SAGE identification of differentiation responsive genes in P19 embryonic cells induced to form cardiomyocytes in vitro. Mech. Dev. 117, 25–74.
Anisimov S. V., Tarasov K. V., Tweedie D., Stern M. D., Wobus A. M., and Boheler K. R. (2002b) SAGE identification of gene transcripts with profiles unique to pluripotent mouse R1 embryonic stem cells. Genomics 79, 169–176.
Bartfai T., Hökfelt T., and Langel Ü. (1993a) Galanin—a neuroendocrine peptide. Crit. Rev. Neurobiol. 7, 229–274.
Bartfai T., Langel Ü., Bedecs K., et al. (1993b) Galanin-receptor ligand M40 peptide distinguishes between putative galanin-receptor subtypes. Proc. Natl. Acad. Sci. USA 90, 11287–11291.
Bartfai T., Lu X., Badie-Mahdavi H., et al. (2004) Galmic, a nonpeptide galanin receptor agonist, affects behaviors in seizure, pain, and forced-swim tests. Proc. Natl. Acad. Sci. USA 101, 10470–10475.
Bauer F. E., Ginsberg L., Venetikou M., MacKay D. J., Burrin J. M., and Bloom S. R. (1986) Growth hormone release in man induced by galanin, a new hypothalamic peptide. Lancet 2, 192–195.
Beal M. F., MacGarvey U., and Swartz K. J. (1990) Galanin immunoreactivity is increased in the nucleus basalis of Meynertin Alzheimer’s disease. Ann. Neurol. 28, 157–161.
Bellido I., Diaz-Cabiale Z., Jimenez-Vasquez P. A., Andbjer B., Mathe A. A., and Fuxe K. (2002) Increased density of galanin binding sites in the dorsal raphe in a genetic rat model of depression. Neurosci. Lett. 317, 101–105.
Blakeman K. H., Hao J. X., Xu X. J., et al. (2003) Hyperalgesia and increased neuropathic pain-like response in mice lacking galanin receptor 1 receptors. Neuroscience 117, 221–227.
Blakeman K. H., Holmberg K., Hao J. X., et al. (2001) Mice over-expressing galanin have elevated heat nociceptive threshold. Neuroreport 12, 423–425.
Borowsky B., Walker M. W., Huang L. Y., et al. (1998) Cloning and characterization of the human galanin GALR2 receptor. Peptides 19, 1771–1781.
Bowser R., Kordower J. H., and Mufson E. J. (1997) A confocal microscopic analysis of galaninergic hyperinnervation of cholinergic basal forebrain neurons in Alzheimer’s disease. Brain Pathol. 7, 723–730.
Branchek T. A., Smith K. E., Gerald C., and Walker M. W. (2000) Galanin receptor subtypes. Trends Pharmacol. Sci. 21, 109–117.
Burgevin M. C., Loquet I., Quarteronet D., and Habert-Ortoli E. (1995) Cloning, pharmacological characterization, and anatomical distribution of a rat cDNA encoding for a galanin receptor. J. Mol. Neurosci. 6, 33–41.
Cai A., Hayes J. D., Patel N., and Hyde J. F. (1999) Targeted overexpression of galanin in lactotrophs of transgenic mice induces hyperprolactinemia and pituitary hyperplasia. Endocrinology 140, 4955–4964.
Calza L., Pozza M., Zanni M., Manzini C. U., Manzini E., and Hökfelt T. (1998) Peptide plasticity in primary sensory neurons and spinal cord during adjuvant-induced arthritis in the rat: an immunocytochemical and in situ hybridization study. Neuroscience 82, 575–589.
Chan-Palay V. (1988a) Galanin hyperinnervates surviving neurons of the human basal nucleus of Meynert in dementias of Alzheimer’s and Parkinson’s disease: a hypothesis for the role of galanin in accentuating cholinergic dysfunction in dementia. J. Comp. Neurol. 273, 543–557.
Chan-Palay V. (1988b) Neurons with galanin innervate cholinergic cells in the human basal forebrain and galanin and acetylcholine coexist. Brain Res. Bull. 21, 465–472.
Chepurnov S. A., Chepurnova N. E., and Berdiev R. K. (1998) Galanin controls excitability of the brain. Ann. NY. Acad. Sci. 865, 547–550.
Ch’ng J. L., Christofides N. D., Anand P., et al. (1985) Distribution of galanin immunoreactivity in the central nervous system and the responses of galanin-containing neuronal pathways to injury. Neuroscience 16, 343–354.
Collins T., Ginsburg D., Boss J. M., Orkin S. H., and Pober J. S. (1985) Cultured human endothelial cells express platelet-derived growth factor B chain: cDNA cloning and structural analysis. Nature 316, 748–750.
Consolo S., Baldi G., Russi G., Civenni G., Bartfai T., and Vezzani A. (1994) Impulse flow dependency of galanin release in vivo in the rat ventral hippocampus. Proc. Natl. Acad. Sci. USA 91, 8047–8051.
Corness J., Shi T. J., Xu Z. Q., Brulet P., and Hökfelt T. (1996) Influence of leukemia inhibitory factor on galanin/GMAP and neuropeptide Y expression in mouse primary sensory neurons after axotomy. Exp. Brain Res. 112, 79–88.
Cortes R., Villar M. J., Verhofstad A., and Hökfelt T. (1990) Effects of central nervous system lesions on the expression of galanin: a comparative in situ hybridization and immunohistochemical study. Proc. Natl. Acad. Sci. USA 87, 7742–7746.
Counts S. E., Perez S. E., Ginsberg S. D., De Lacalle S., and Mufson E. J. (2003) Galanin in Alzheimer disease. Mol. Interv. 3, 137–156.
Crawley J. N. (1996) Minireview. Galanin-acetylcholine interactions: relevance to memory and Alzheimer’s disease. Life Sci. 58, 2185–2199.
Davis T. M., Burrin J. M., and Bloom S. R. (1987) Growth hormone (GH) release in response to GH-releasing hormone in man is 3-fold enhanced by galanin. J. Clin. Endocrinol. Metab. 65, 1248–1252.
de Lacalle S., Kulkarni S., and Mufson E. J. (1997) Plasticity of galaninergic fibers following neurotoxic damage within the rat basal forebrain: initial observations. Exp. Neurol. 146, 361–366.
Deecher D. C., Mash D. C., Staley J. K., and Mufson E. J. (1998) Characterization and localization of galanin receptors in human entorhinal cortex. Regul. Pept. 73, 149–159.
Degerman A., Chun D., Nguyen T. B., et al. (2002) Local action of estrogen and thyroid hormone on vasoactive intestinal peptide (VIP) and galanin gene expression in the rat anterior pituitary. Neuropeptides 36, 50–57.
Diez M., Danner S., Frey P., et al. (2003) Neuropeptide alterations in the hippocampal formation and cortex of transgenic mice overexpressing beta-amyloid precursor protein (APP) with the Swedish double mutation (APP23). Neurobiol. Dis. 14, 579–594.
Diez M., Koistinaho J., Kahn K., Games D., and Hökfelt T. (2000) Neuropeptides in hippocampus and cortex in transgenic mice overexpressing V717F beta-amyloid precursor protein—initial observations. Neuroscience 100, 259–286.
Elliott-Hunt C. R., Marsh B., Bacon A., Pope R., Vanderplank P., and Wynick D. (2004) Galanin acts as a neuroprotective factor to the hippocampus. Proc. Natl. Acad. Sci. USA 101, 5105–5110
Elvander E., Schott P.A., Sandin J., et al. (2004) Intraseptal muscarinic ligands and galanin: influence on hippocampal acetylcholine and cognition. Neuroscience 126, 541–557.
Ericson E. and Ahlenius S. (1999) Suggestive evidence for inhibitory effects of galanin on mesolimbic dopaminergic neurotransmission. Brain Res. 822, 200–209.
Fathi Z., Battaglino P. M., et al. (1998) Molecular characterization, pharmacological properties and chromosomal localization of the human GALR2 galanin receptor. Brain Res. Mol. Brain Res. 58, 156–169.
Fathi Z., Cunningham A. M., Iben L. G., et al. (1997) Cloning, pharmacological characterization and distribution of a novel galanin receptor. Brain. Res. Mol. Brain Res. 51, 49–59.
Fetissov S. O., Jacoby A. S., Brumovsky P. R., Shine J., Iismaa T. P., and Hökfelt T. (2003) Altered hippocampal expression of neuropeptides in seizure-prone GALR1 knockout mice. Epilepsia 44, 1022–1033.
Finn P. D., Pau K. Y., Spies H. G., Cunningham M. J., Clifton D. K., and Steiner R. A. (2000) Galanin’s functional significance in the regulation of the neuroendocrine reproductive axis of the monkey. Neuroendocrinology 71, 16–26.
Fisone G., Bartfai T., Nilsson S., and Hökfelt T. (1991) Galanin inhibits the potassium-evoked release of acetylcholine and the muscarinic receptor-mediated stimulation of phosphoinositide turnover in slices of monkey hippocampus. Brain Res. 568, 279–284.
Fisone G., Wu C. F., Consolo S., et al. (1987) Galanin inhibits acetylcholine release in the ventral hippocampus of the rat: histochemical, autoradiographic, in vivo, and in vitro studies. Proc. Natl. Acad. Sci. USA 84, 7339–7343.
Flatters S. J., Fox A. J., and Dickenson A. H. (2002) Nerve injury induces plasticity that results in spinal inhibitory effects of galanin. Pain 98, 249–258.
Florén A., Land T., and Langel Ü. (2000) Galanin receptor subtypes and ligand binding. Neuropeptides 34, 331–337.
Fuxe K., Jansson A., Diaz-Cabiale Z., et al. (1998) Galanin modulates 5-hydroxytryptamine functions. Focus on galanin and galanin fragment/5-hydroxytryptamine1A receptor interactions in the brain. Ann. N. Y. Acad. Sci. 863, 274–290.
Fuxe K., von Euler G., Agnati L. F., and Ögren S. O. (1988a) Galanin selectively modulates 5-hydroxytryptamine 1A receptors in the rat ventral limbic cortex. Neurosci. Lett. 85, 163–167.
Fuxe K., Ögren S. O., Jansson A., Cintra A., Harfstrand A., and Agnati L. F. (1988b) Intraventricular injections of galanin reduces 5-HT metabolism in the ventral limbic cortex, the hippocampal formation and the fronto-parietal cortex of the male rat. Acta. Physiol. Scand. 133, 579–581.
Gabriel S. M., Bierer L. M., Davidson M., Purohit D. P., Perl D. P., and Harotunian V. (1994) Galanin-like immunoreactivity is increased in the postmortem cerebral cortex from patients with Alzheimer’s disease. J. Neurochem. 62, 1516–1523.
Gabriel S. M., Kaplan L. M., Martin J. B., and Koenig J. I. (1989) Tissue-specific sex differences in galanin-like immunoreactivity and galanin mRNA during development in the rat. Peptides 10, 369–374.
Gentleman S. M., Falkai P., Bogerts B., Herrero M. T., Polak J. M., and Roberts G. W. (1989) Distribution of galanin-like immunoreactivity in the human brain. Brain Res. 505, 311–315.
Gomez-Isla T., Price J. L., McKeel D. W., Jr., Morris J. C., Growdon J. H., and Hyman B. T. (1996) Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer’s disease. J. Neurosci. 16, 4491–4500.
Grass S., Jacoby A. S., Iismaa T. P., Crawley J. N., Xu X. J., and Wiesenfeld-Hallin Z. (2003) Flexor reflex excitability in mice lacking galanin receptor galanin-R1. Neurosci. Lett. 345, 153–156.
Grenbäck E., Bjellerup P., Wallerman E., et al. (2004) Galanin in pituitary adenomas. Regul. Pept. 117, 127–319.
Haberman R. P., Samulski R. J., and McCown T. J. (2003) Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion. Nat. Med. 9, 1076–1080.
Habert-Ortoli E., Amiranoff B., Loquet I., Laburthe M., and Mayaux J. F. (1994) Molecular cloning of a functional human galanin receptor. Proc. Natl. Acad. Sci. USA 91, 9780–9783.
Hao J. X., Shi T. J., Xu I. S., et al. (1999) Intrathecal galanin alleviates allodynia-like behaviour in rats after partial peripheral nerve injury. Eur. J. Neurosci. 11, 427–432.
Harrison P. S., and Henderson Z. (1999) Quantitative evidence for increase in galanin-immunoreactive terminals in the hippocampal formation following entorhinal cortex lesions in the adult rat. Neurosci. Lett. 266, 41–44.
Harro J., and Oreland L. (2001) Depression as a spreading adjustment disorder of monoaminergic neurons: a case for primary implication of the locus coeruleus. Brain Res. Brain Res. Rev. 38, 79–128.
Hartonian I., Mufson E. J., and De Lacalle S. (2002) Long-term plastic changes in galanin innervation in the rat basal forebrain. Neuroscience 115, 787–795.
Holmes A., Heilig M., Rupniak N. M., Steckler T., and Griebel G. (2003a) Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol. Sci. 24, 580–588.
Holmes A., Li Q., Koenig E. A., et al. (2004) Phenotypic assessment of galanin overexpressing and galanin receptor R1 knockout mice in the tail suspension test for depression-related behavior. Psychopharmacology (Berl) 178, 276–285.
Holmes F. E., Bacon A., Pope R. J., et al. (2003b) Transgenic overexpression of galanin in the dorsal root ganglia modulates pain-related behavior. Proc. Natl. Acad. Sci. USA 100, 6180–6185.
Holmes F. E., Mahoney S., King V. R., et al. (2000) Targeted disruption of the galanin gene reduces the number of sensory neurons and their regenerative capacity. Proc. Natl. Acad. Sci. U S A 97, 11563–11568.
Hooi S. C., Koenig J. I., Abraczinskas D. R., and Kaplan L. M. (1997) Regulation of anterior pituitary galanin gene expression by thyroid hormone. Brain Res. Mol. Brain Res. 51, 15–22.
Hulting A. L., Land T., Berthold M., Langel Ü., Hökfelt T., and Bartfai T. (1993) Galanin receptors from human pituitary tumors assayed with human galanin as ligand. Brain Res. 625, 173–176.
Hulting A. L., Meister B., Grimelius L., Wersall J., Änggård A., and Hökfelt T. (1989) Production of a galanin-like peptide by a human pituitary adenoma: immunohistochemical evidence. Acta. Physiol. Scand. 137, 561–562.
Husum H., Van Kammen D., Termeer E., Bolwig G., and Mathe A. (2003) Topiramate normalizes hippocampal NPY-LI in flinders sensitive line ‘depressed’ rats and upregulates NPY, galanin, and CRH-LI in the hypothalamus: implications for mood-stabilizing and weight loss-inducing effects. Neuropsychopharmacology 28, 1292–1299.
Hygge-Blakeman K., Brumovsky P., Hao J. X., et al. (2004) Galanin over-expression decreases the development of neuropathic pain-like behaviors in mice after partial sciatic nerve injury. Brain Res. 1025, 152–158.
Hökfelt T., Millhorn D., Seroogy K., et al. (1987a) Coexistence of peptides with classical neurotransmitters. Experientia 43, 768–780.
Hökfelt T., Wiesenfeld-Hallin Z., Villar M., and Melander T. (1987b) Increase of galanin-like immunoreactivity in rat dorsal root ganglion cells after peripheral axotomy. Neurosci. Lett. 83, 217–220.
Hökfelt T., Xu Z. Q., Shi T. J., Holmberg K., and Zhang X. (1998) Galanin in ascending systems. Focus on coexistence with 5-hydroxytryptamine and noradrenaline. Ann. N. Y. Acad. Sci. 863, 252–263.
Jacobowitz D. M., Kresse A., and Skofitsch G. (2004) Galanin in the brain: chemoarchitectonics and brain cartography—a historical review. Peptides 25, 433–464.
Jacoby A. S., Hort Y. J., Constantinescu G., Shine J., and Iismaa T. P. (2002) Critical role for GALR1 galanin receptor in galanin regulation of neuroendocrine function and seizure activity. Brain Res. Mol. Brain Res. 107, 195–200.
Jhamandas J. H., Harris K. H., MacTavish D., and Jassar B. S. (2002) Novel excitatory actions of galanin on rat cholinergic basal forebrain neurons: implications for its role in Alzheimer’s disease. J. Neurophysiol. 87, 696–704.
Ji R. R., Zhang Q., Pettersson R. F., and Hökfelt T. (1996) aFGF, bFGF and NGF differentially regulate neuropeptide expression in dorsal root ganglia after axotomy and induce autotomy. Regul. Pept. 66, 179–189.
Ji R. R., Zhang X., Zhang Q., et al. (1995) Central and peripheral expression of galanin in response to inflammation. Neuroscience 68, 563–576.
Jimenez-Andrade J. M., Zhou S., Du J., et al. (2004) Pro-nociceptive role of peripheral galanin in inflammatory pain. Pain 110, 10–21.
Kaplan L. M., Gabriel S. M., Koenig J. I., et al. (1988) Galanin is an estrogen-inducible, secretory product of the rat anterior pituitary. Proc. Natl. Acad. Sci. USA 85, 7408–7412.
Kask, K. Berthold M., Bourne J., Andell S., Langel Ü., and Bartfai T. (1995) Binding and agonist/antagonist actions of M35, galanin(1–13)-bradykinin(2–9) amide chimeric peptide, in Rin m 5F insulinoma cells. Regul. Pept. 59, 341–348.
Kehr J., Yoshitake T., Wang F. H., et al. (2002) Galanin is a potent in vivo modulator of mesencephalic serotonergic neurotransmission. Neuropsychopharmacology 27, 341–356.
Kehr J., Yoshitake T., Wang F. H., et al. (2001) Microdialysis in freely moving mice: determination of acetylcholine, serotonin and noradrenaline release in galanin transgenic mice. J. Neurosci. Methods 109, 71–80.
Kerekes N., Landry M., Rydh-Rinder M., and Hökfelt T. (1997) The effect of NGF, BDNF and bFGF on expression of galanin in cultured rat dorsal root ganglia. Brain Res. 754, 131–141.
Kerr B. J., Cafferty W. B., Gupta Y. K., et al. (2000a) Galanin knockout mice reveal nociceptive deficits following peripheral nerve injury. Eur. J. Neurosci. 12, 793–802.
Kerr B. J., Gupta Y., Pope R., Thompson S. W., Wynick D., and McMahon S. B. (2001) Endogenous galanin potentiates spinal nociceptive processing following inflammation. Pain 93, 267–277.
Kerr B. J., Wynick D., Thompson S. W., and McMahon S. B. (2000b) The biological role of galanin in normal and neuropathic states. Prog. Brain Res. 129, 219–230.
Kinney G. A., Emmerson P. J., and Miller R. J. (1998) Galanin receptor-mediated inhibition of glutamate release in the arcuate nucleus of the hypothalamus. J. Neurosci. 18, 3489–3500.
Kinney J. W., Barr A. M., Conti B., Behrens M., and Bartfai T. (2004) Society for Neuroscience, San Diego, USA.
Kokaia M., Holmberg K., Nanobashvili A., et al. (2001) Suppressed kindling epileptogenesis in mice with ectopic overexpression of galanin. Proc. Natl. Acad. Sci. USA 98, 14006–14011.
Kolakowski L. F., Jr., O’Neill G. P., Howard A. D., et al. (1998) Molecular characterization and expression of cloned human galanin receptors GALR2 and GALR3. J. Neurochem. 71, 2239–2251.
Kordower J. H., Chu Y., Stebbins G. T., et al. (2001) Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann. Neurol. 49, 202–213.
Kordower J. H., Le H. K., and Mufson E. J. (1992) Galanin immunoreactivity in the primate central nervous system. J. Comp. Neurol. 319, 479–500.
Koshiyama H., Kato Y., Inoue T., et al. (1987) Central galanin stimulates pituitary prolactin secretion in rats: possible involvement of hypothalamic vasoactive intestinal polypeptide. Neurosci. Lett. 75, 49–54.
Kowall N. W. and Beal M. F. (1989) Galanin-like immunoreactivity is present in human substantia innominata and in senile plaques in Alzheimer’s disease. Neurosci. Lett. 98, 118–213.
Lamour Y., Senut M. C., Dutar P., and Bassant M. H. (1988) Neuropeptides and septo-hippocampal neurons: electrophysiological effects and distributions of immunoreactivity. Peptides 9, 1351–1359.
Landry M., Holmberg K., Zhang X., and Hökfelt T. (2000) Effect of axotomy on expression of NPY, galanin, and NPY Y1 and Y2 receptors in dorsal root ganglia and the superior cervical ganglion studied with double-labeling in situ hybridization and immunohistochemistry. Exp. Neurol. 162, 361–384.
Lang R., Berger A., Hermann A., and Kofler B. (2001) Biphasic response to human galanin of extracellular acidification in human Bowes melanoma cells. Eur. J. Pharmacol. 423, 135–141.
Laplante F., Crawley J. N., and Quirion R. (2004) Selective reduction in ventral hippocampal acetylcholine release in awake galanin-treated rats and galanin-overexpressing transgenic mice. Regul. Pept. 122, 91–98.
Leung B., Iisma T. P., Leung K. C., Hort Y. J., Turner J., Sheehy J. P., et al. (2002) Galanin in human pituitary adenomas: frequency and clinical significance. Clin. Endocrinol. (Oxf). 56, 397–403.
Lin E. J., Richichi C., Young D., Baer K., Vezzani A., and During M. J. (2003) Recombinant AAV-mediated expression of galanin in rat hippocampus suppresses seizure development. Eur. J. Neurosci. 18, 2087–2092.
Liu H. X., Brumovsky P., Schmidt R., et al. (2001) Receptor subtype-specific pronociceptive and analgesic actions of galanin in the spinal cord: selective actions via GalR1 and GalR2 receptors. Proc. Natl. Acad. Sci. USA 98, 9960–9964.
Liu H. X. and Hökfelt T. (2002) The participation of galanin in pain processing at the spinal level. Trends. Pharmacol. Sci. 23, 468–474.
Lu X., Barr A. M., Kinney J. W., et al. (2005) A role for galanin in antidepressant actions with a focus on the dorsal raphe nucleus. Proc. Natl. Acad. Sci. USA. 102, 874–879.
Lundström L., Sollenberg U., Brewer A., et al. (2004) A Galanin Receptor subtype 1 Specific Agonist. Int. J. Peptide Res. Ther. 11, 17–27.
Ma W. and Bisby M. A. (1997) Differential expression of galanin immunoreactivities in the primary sensory neurons following partial and complete sciatic nerve injuries. Neuroscience 79, 1183–1195.
Ma X., Tong Y. G., Schmidt R., et al. (2001) Effects of galanin receptor agonists on locus coeruleus neurons. Brain Res. 919, 169–174.
Mahoney S. A., Hosking R., Farrant S., et al. (2003) The second galanin receptor GalR2 plays a key role in neurite outgrowth from adult sensory neurons. J. Neurosci. 23, 416–421.
Maiter D. M., Hooi S. C., Koenig J. I., and Martin J. B. (1990) Galanin is a physiological regulator of spontaneous pulsatile secretion of growth hormone in the male rat. Endocrinology 126, 1216–1222.
Marti E., Gibson S. J., Polak J. M., et al. (1987) Ontogeny of peptide- and amine-containing neurones in motor, sensory, and autonomic regions of rat and human spinal cord, dorsal root ganglia, and rat skin. J. Comp. Neurol. 266, 332–359.
Mazarati A., Langel Ü., and Bartfai T. (2001) Galanin: an endogenous anticonvulsant? Neuroscientist 7, 506–517.
Mazarati A., Lu X., Kilk K., Langel Ü., Wasterlain C., and Bartfai T. (2004a) Galanin type 2 receptors regulate neuronal survival, susceptibility to seizures and seizure-induced neurogenesis in the dentate gyrus. Eur. J. Neurosci. 19, 3235–3244.
Mazarati A., Lu X., Shinmei S., Badie-Mahdavi H., and Bartfai T. (2004b) Patterns of seizures, hippocampal injury and neurogenesis in three models of status epilepticus in galanin receptor type 1 (GalR1) knockout mice. Neuroscience 128, 431–441.
Mazarati A. and Wasterlain C. G. (2002) Anticonvulsant effects of four neuropeptides in the rat hippocampus during self-sustaining status epilepticus. Neurosci. Lett. 331, 123–127.
Mazarati A. M., Halaszi E., and Telegdy G. (1992) Anticonvulsive effects of galanin administered into the central nervous system upon the picrotoxin-kindled seizure syndrome in rats. Brain Res. 589, 164–166.
Mazarati A. M., Hohmann J. G., Bacon A., et al. (2000) Modulation of hippocampal excitability and seizures by galanin. J. Neurosci. 20, 6276–6281.
Mazarati A. M., Liu H., Soomets U., et al. (1998) Galanin modulation of seizures and seizure modulation of hippocampal galanin in animal models of status epilepticus. J. Neurosci. 18, 10070–10077.
Melander T., Hökfelt T., and Rökaeus A. (1986a) Distribution of galaninlike immunoreactivity in the rat central nervous system. J. Comp. Neurol. 248, 475–517.
Melander T., Hökfelt T., Rökaeus A., et al. (1986b) Coexistence of galanin-like immunoreactivity with catecholamines, 5-hydroxytryptamine, GABA and neuropeptides in the rat CNS. J. Neurosci. 6, 3640–3654.
Melander T., Staines W. A., Hökfelt T., et al. (1985) Galanin-like immunoreactivity in cholinergic neurons of the septum-basal forebrain complex projecting to the hippocampus of the rat. Brain Res. 360, 130–138.
Melander T., Staines W. A., and Rokaeus A. (1986c) Galanin-like immunoreactivity in hippocampal afferents in the rat, with special reference to cholinergic and noradrenergic inputs. Neuroscience 19, 223–240.
Mennicken F., Hoffert C., Pelletier M., Ahmad S., and O’Donnell D. (2002) Restricted distribution of galanin receptor 3 (GalR3) mRNA in the adult rat central nervous system. J. Chem. Neuroanat. 24, 257–268.
Mercer E. H., Hoyle G. W., Kapur R. P., Brinster R. L., and Palmiter R. D. (1991) The dopamine beta-hydroxylase gene promoter directs expression of E. coli lacZ to sympathetic and other neurons in adult transgenic mice. Neuron 7, 703–716.
Mufson E. J., Bothwell M., and Kordower J. H. (1989) Loss of nerve growth factor receptor-containing neurons in Alzheimer’s disease: a quantitative analysis across subregions of the basal forebrain. Exp. Neurol. 105, 221–232.
Mufson E. J., Cochran E., Benzing W., and Kordower J. H. (1993) Galaninergic innervation of the cholinergic vertical limb of the diagonal band (Ch2) and bed nucleus of the stria terminalis in aging, Alzheimer’s disease and Down’s syndrome. Dementia 4, 237–250.
Mufson E. J., Deecher D. C., Basile M., Izenwasse S., and Mash D. C. (2000) Galanin receptor plasticity within the nucleus basalis in early and late Alzheimer’s disease: an in vitro autoradiographic analysis. Neuropharmacology 39, 1404–1412.
Murakami Y., Kato Y., Koshiyama H., Inoue T., Yanaihara N., and Imura H. (1987) Galanin stimulates growth hormone (GH) secretion via GH-releasing factor (GRF) in conscious rats. Eur. J. Pharmacol. 136, 415–418.
Murck H., Antonijevic I. A., Frieboes R. M., Maier P., Schier T., and Steiger A. (1999) Galanin has REM-sleep deprivation-like effects on the sleep EEG in healthy young men. J. Psychiatr. Res. 33, 225–232.
Murck H., Held K., Ziegenbein M., Kunzel H., Holsboer F., and Steiger A. (2004) Intravenous administration of the neuropeptide galanin has fast antidepressant efficacy and affects the sleep EEG. Psychoneuroendocrinology 29, 1205–1211.
Nahin R. L., Ren K., De Leon M., and Ruda M. (1994) Primary sensory neurons exhibit altered gene expression in a rat model of neuropathic pain. Pain 58, 95–108.
Nordström O., Melander T., Hökfelt T., Bartfai T., and Goldstein M. (1987) Evidence for an inhibitory effect of the peptide galanin on dopamine release from the rat median eminence. Neurosci. Lett. 73, 21–26.
O’Donnell D., Ahmad S., Wahlestedt C., and Walker P. (1999) Expression of the novel galanin receptor subtype GALR2 in the adult rat CNS: distinct distribution from GALR1. J. Comp. Neurol. 409, 469–481.
Ohtaki T., Kumano S., Ishibashi Y., et al. (1999) Isolation and cDNA cloning of a novel galanin-like peptide (GALP) from porcine hypothalamus. J. Biol. Chem. 274, 37041–37045.
O’Meara G., Coumis U., Ma S. Y., et al. (2000) Galanin regulates the postnatal survival of a subset of basal forebrain cholinergic neurons. Proc. Natl. Acad. Sci. USA 97, 11569–11574.
Ottlecz A., Samson W. K., and McCann S. M. (1986) Galanin: evidence for a hypothalamic site of action to release growth hormone. Peptides 7, 51–53.
Ottlecz A., Snyder G. D., and McCann S. M. (1988) Regulatory role of galanin in control of hypothalamic-anterior pituitary function. Proc. Natl. Acad. Sci. USA 85, 9861–9865.
Parker E. M., Izzarelli D. G., Nowak H. P., et al. (1995) Cloning and characterization of the rat GALR1 galanin receptor from Rin14B insulinoma cells. Brain Res. Mol. Brain Res. 34, 179–189.
Perez S., Basile M., Mash D. C., and Mufson E. J. (2002) Galanin receptor over-expression within the amygdala in early Alzheimer’s disease: an in vitro autoradiographic analysis. J. Chem. Neuroanat. 24, 109–116.
Perez S. E., Wynick D., Steiner R. A., and Mufson E. J. (2001) Distribution of galaninergic immunoreactivity in the brain of the mouse. J. Comp. Neurol. 434, 158–185.
Perumal P. and Vrontakis M. E. (2003) Transgenic mice over-expressing galanin exhibit pituitary adenomas and increased secretion of galanin, prolactin and growth hormone. J. Endocrinol. 179, 145–154.
Pieribone V. A., Xu Z. Q., Zhang X., Grillner S., Bartfai T., and Hökfelt T. (1995) Galanin induces a hyperpolarization of norepinephrine-containing locus coeruleus neurons in the brainstem slice. Neuroscience 64, 861–874.
Planas B., Kolb P. E., Raskind M. A., and Miller M. A. (1997) Nerve growth factor induces galanin gene expression in the rat basal forebrain: implications for the treatment of cholinergic dysfunction. J. Comp. Neurol. 379, 563–570.
Pooga M., Soomets U., Hällbrink M., et al. (1998) Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat. Biotechnol. 16, 857–861.
Pramanik A., and Ögren S. O. (1993) Galanin stimulates striatal acetylcholine release via a mechanism unrelated to cholinergic receptor stimulation. Regul. Pept. 45, 353–362.
Puar M. S., Barrabee E., Hallade M., and Patel M. (2000) Sch 420789: a novel fungal metabolite with phospholipase D inhibitory activity. J. Antibiot. (Tokyo) 53, 837–838.
Razani H., Diaz-Cabiale Z., Fuxe K., and Ögren S. O. (2000) Intraventricular galanin produces a time-dependent modulation of 5-HT1A receptors in the dorsal raphe of the rat. Neuroreport 11, 3943–3948.
Rodriguez-Puertas R., Nilsson S., Pascual J., Pazos A., and Hökfelt T. (1997) 125I-galanin binding sites in Alzheimer’s disease: increases in hippocampal subfields and a decrease in the caudate nucleus. J. Neurochem. 68, 1106–1113.
Rökaeus A., Melander T., Hökfelt T., Lundberg J. M., Tatemoto K., Carlquist M., et al. (1984) A galanin-like peptide in the central nervous system and intestine of the rat. Neurosci. Lett. 47, 161–166.
Saar K., Mazarati A. M., Mahlapuu R., et al. (2002) Anticonvulsant activity of a nonpeptide galanin receptor agonist. Proc. Natl. Acad. Sci. USA 99, 7136–7141.
Sahu A., Crowley W. R., Tatemoto K., Balasubramaniam A., and Kalra S. P. (1987) Effects of neuropeptide Y, NPY analog (norleucine4-NPY), galanin and neuropeptide K on LH release in ovariectomized (ovx) and ovx estrogen, progesterone-treated rats. Peptides 8, 921–926.
Sakurai E., Maeda T., Kaneko S., Akaike A., and Satoh M. (1996) Galanin inhibits long-term potentiation at Schaffer collateral-CA1 synapses in guinea-pig hippocampal slices. Neurosci. Lett. 212, 21–24.
Sano T., Vrontakis M. E., Kovacs K., Asa S. L., and Friesen H. G. (1991) Galanin immunoreactivity in neuroendocrine tumors. Arch. Pathol. Lab. Med. 115, 926–929.
Sargent P. A., Kjaer K. H., Bench C. J., et al. (2000) Brain serotonin 1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch. Gen. Psychiatry 57, 174–180.
Scott M. K., Ross T. M., Lee D. H., et al. (2000) 2,3-Dihydro-dithiin and -dithiepine-1,1,4,4-tetroxides: small molecule non-peptide antagonists of the human galanin hGAL-1 receptor. Bioorg. Med. Chem. 8, 1383–1391.
Seutin V., Verbanck P., Massotte L., and Dresse A. (1989) Galanin decreases the activity of locus coeruleus neurons in vitro. Eur. J. Pharmacol. 164, 373–376.
Sevcik J., Finta E. P., and Illes P. (1993) Galanin receptors inhibit the spontaneous firing of locus coeruleus neurones and interact with mu-opioid receptors. Eur. J. Pharmacol. 230, 223–230.
Simmons D. R., Spike R. C., and Todd A. J. (1995) Galanin is contained in GABAergic neurons in the rat spinal dorsal horn. Neurosci. Lett. 187, 119–122.
Skofitsch G. and Jacobowitz D. M. (1985a) Galanin-like immunoreactivity in capsaicin sensitive sensory neurons and ganglia. Brain Res. Bull. 15, 191–195.
Skofitsch G. and Jacobowitz D. M. (1985b) Immunohistochemical mapping of galanin-like neurons in the rat central nervous system. Peptides 6, 509–546.
Skofitsch G. and Jacobowitz D. M. (1986a) Quantitative distribution of galanin-like immunoreactivity in the rat central nervous system. Peptides 7, 609–613.
Skofitsch G., Sills M. A., and Jacobowitz D. M. (1986b) Autoradiographic distribution of 125I-galanin binding sites in the rat central nervous system. Peptides 7, 1029–1042.
Smith K. E., Forray C., Walker M. W., et al. (1997) Expression cloning of a rat hypothalamic galanin receptor coupled to phosphoinositide turnover. J. Biol. Chem. 272, 24612–26616.
Smith K. E., Walker M. W., Artymyshyn R., et al. (1998) Cloned human and rat galanin GALR3 receptors. Pharmacology and activation of G-protein inwardly rectifying K+ channels. J. Biol. Chem. 273, 23321–23326.
Steiner R. A., Hohmann J. G., Holmes A., et al. (2001) Galanin transgenic mice display cognitive and neurochemical deficits characteristic of Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 98, 4184–4189.
Sten Shi T. J., Zhang X., Holmberg K., Xu Z. Q., and Hökfelt T. (1997) Expression and regulation of galanin-R2 receptors in rat primary sensory neurons: effect of axotomy and inflammation. Neurosci. Lett. 237, 57–60.
Sukumaran M., Waxman S. G., Wood J. N., and Pachnis V. (2001) Flanking regulatory sequences of the locus encoding the murine GDNF receptor, c-ret, directs lac Z (beta-galactosidase) expression in developing somatosensory system. Dev. Dyn. 222, 389–402.
Tatemoto K., Rökaeus A., Jörnvall H., McDonald T. J., and Mutt V. (1983) Galanin — a novel biologically active peptide from porcine intestine. FEBS Lett. 164, 124–128.
Toppila J., Stenberg D., Alanko L., et al. (1995) REM sleep deprivation induces galanin gene expression in the rat brain. Neurosci. Lett. 183, 171–174.
Walker L. C., Rance N. E., Price D. L., and Young W. S., 3rd (1991) Galanin mRNA in the nucleus basalis of Meynert complex of baboons and humans. J. Comp. Neurol. 303, 113–120.
Wang H. Y., Wild K. D., Shank R. P., and Lee D. H. (1999) Galanin inhibits acetylcholine release from rat cerebral cortex via a pertussis toxin-sensitive G(i)protein. Neuropeptides 33, 197–205.
Wang R., Guo W., Ossipov M. H., Vanderah T. W., Porreca F., and Lai J. (2003) Glial cell line-derived neurotrophic factor normalizes neurochemical changes in injured dorsal root ganglion neurons and prevents the expression of experimental neuropathic pain. Neuroscience 121, 815–824.
Wang S., Hashemi T., Fried S., Clemmons A. L., and Hawes B. E. (1998) Differential intracellular signaling of the GalR1 and GalR2 galanin receptor subtypes. Biochemistry 37, 6711–6717.
Wang S., Hashemi T., He C., Strader C., and Bayne M. (1997a) Molecular cloning and pharmacological characterization of a new galanin receptor subtype. Mol. Pharmacol. 52, 337–343.
Wang S., He C., Hashemi T., and Bayne M. (1997b) Cloning and expressional characterization of a novel galanin receptor. Identification of different pharmacophores within galanin for the three galanin receptor subtypes. J. Biol. Chem. 272, 31949–31952.
Weiss J. M., Bonsall R. W., Demetrikopoulos M. K., Emery M. S., and West C. H. (1998) Galanin: a significant role in depression? Ann. N Y. Acad. Sci. 863, 364–382.
Vereecken T. H., Vogels O. J., and Nieuwenhuys R. (1994) Neuron loss and shrinkage in the amygdala in Alzheimer’s disease. Neurobiol. Aging 15, 45–54.
Wiesenfeld-Hallin Z., Villar M. J., and Hökfelt T. (1989) The effects of intrathecal galanin and C-fiber stimulation on the flexor reflex in the rat. Brain Res. 486, 205–213.
Wiesenfeld-Hallin Z., Xu X. J., Langel Ü., Bedecs K., Hökfelt T., and Bartfai T. (1992) Galanin-mediated control of pain: enhanced role after nerve injury. Proc. Natl. Acad. Sci. USA 89, 3334–3337.
Wiesenfeld-Hallin Z., Xu X. J., Villar M. J., and Hökfelt T. (1990) Intrathecal galanin potentiates the spinal analgesic effect of morphine: electrophysiological and behavioural studies. Neurosci. Lett. 109, 217–221.
Villar M. J., Cortes R., Theodorsson E., et al. (1989) Neuropeptide expression in rat dorsal root ganglion cells and spinal cord after peripheral nerve injury with special reference to galanin. Neuroscience 33, 587–604.
Villar M. J., Meister B., Cortes R., Schalling M., Morris M., and Hökfelt T. (1990) Neuropeptide gene expression in hypothalamic magnocellular neurons of normal and hypophysectomized rats: a combined immunohistochemical and in situ hybridization study. Neuroscience 36, 181–199.
Villar M. J., Wiesenfeld-Hallin Z., Xu X. J., Theodorsson E., Emson P. C., and Hökfelt T. (1991) Further studies on galanin-, substance P-, and CGRP-like immunoreactivities in primary sensory neurons and spinal cord: effects of dorsal rhizotomies and sciatic nerve lesions. Exp. Neurol. 112, 29–39.
Wittau N., Grosse R., Kalkbrenner F., Gohla A., Schultz G., and Gudermann T. (2000) The galanin receptor type 2 initiates multiple signaling pathways in small cell lung cancer cells by coupling to G(q), G(i) and G(12) proteins. Oncogene 19, 4199–4209.
Vogels O. J., Broere C. A., ter Laak H. J., ten Donkelaar H. J., Nieuwenhuys R., and Schulte B. P. (1990) Cell loss and shrinkage in the nucleus basalis Meynert complex in Alzheimer’s disease. Neurobiol. Aging 11, 3–13.
Wrenn C. C., and Crawley J. N. (2001) Pharmacological evidence supporting a role for galanin in cognition and affect. Prog. Neuropsychopharmacol. Biol. Psychiatry 25, 283–299.
Wrenn C. C., Kinney J. W., Marriott L. K., et al. (2004) Learning and memory performance in mice lacking the GAL-R1 subtype of galanin receptor. Eur. J. Neurosci. 19, 1384–1396.
Vrontakis M. E., Sano T., Kovacs K., and Friesen H. G. (1990) Presence of galanin-like immunoreactivity in nontumorous corticotrophs and corticotroph adenomas of the human pituitary. J. Clin. Endocrinol. Metab. 70, 747–751.
Vrontakis M. E., Yamamoto T., Schroedter I. C., Nagy J. I., and Friesen H. G. (1989) Estrogen induction of galanin synthesis in the rat anterior pituitary gland demonstrated by in situ hybridization and immunohistochemistry. Neurosci. Lett. 100, 59–64.
Wynick D., Small C. J., Bacon A., et al. (1998) Galanin regulates prolactin release and lactotroph proliferation. Proc. Natl. Acad. Sci. USA 95, 12671–12676.
Xu I. S., Grass S., Xu X. J., and Wiesenfeld-Hallin Z. (1998a) On the role of galanin in mediating spinal flexor reflex excitability in inflammation. Neuroscience 85, 827–835.
Xu S., Zhang Y., Lundeberg T., and Yu L. (2000a) Effects of galanin on wide-dynamic range neuron activity in the spinal dorsal horn of rats with sciatic nerve ligation. Regul. Pept. 95, 19–23.
Xu X. J., Hökfelt T., Bartfai T., and Wiesenfeld-Hallin Z. (2000b) Galanin and spinal nociceptive mechanisms: recent advances and therapeutic implications. Neuropeptides 34, 137–147.
Xu X. J., Wiesenfeld-Hallin Z., and Hökfelt T. (1991) Intrathecal galanin blocks the prolonged increase in spinal cord flexor reflex excitability induced by conditioning stimulation of unmyelinated muscle afferents in the rat. Brain Res. 541, 350–353.
Xu X. J., Wiesenfeld-Hallin Z., Villar M. J., Fahrenkrug J., and Hökfelt T. (1990) On the Role of Galanin, Substance P and Other Neuropeptides in Primary Sensory Neurons of the Rat: Studies on Spinal Reflex Excitability and Peripheral Axotomy. Eur. J. Neurosci. 2, 733–743.
Xu Z. Q., Bartfai T., Langel Ü., and Hökfelt T. (1998b) Effects of three galanin analogs on the outward current evoked by galanin in locus coeruleus. Ann. NY. Acad. Sci. 863, 459–465.
Xu Z. Q., and Hökfelt T. (1997) Expression of galanin and nitric oxide synthase in subpopulations of serotonin neurons of the rat dorsal raphe nucleus. J. Chem. Neuroanat. 13, 169–187.
Xu Z. Q., Shi T. J., and Hökfelt T. (1996a) Expression of galanin and a galanin receptor in several sensory systems and bone anlage of rat embryos. Proc. Natl. Acad. Sci. USA 93, 14901–14905.
Xu Z. Q., Shi T. J., and Hökfelt T. (1998c) Galanin/GMAP-and NPY-like immunoreactivities in locus coeruleus and noradrenergic nerve terminals in the hippocampal formation and cortex with notes on the galanin-R1 and -R2 receptors. J. Comp. Neurol. 392, 227–251.
Xu Z. Q., Shi T. J., Landry M., and Hökfelt T. (1996b) Evidence for galanin receptors in primary sensory neurones and effect of axotomy and inflammation. Neuroreport 8, 237–242.
Xu Z. Q., Zhang X., Pieribone V. A., Grillner S., and Hökfelt T. (1998d) Galanin-5-hydroxytryptamine interactions: electrophysiological, immunohistochemical and in situ hybridization studies on rat dorsal raphe neurons with a note on galanin R1 and R2 receptors. Neuroscience 87, 79–94.
Yoshida M., Yokoo H., Tanaka T., Emoto H., and Tanaka M. (1994) Opposite changes in the mesolimbic dopamine metabolism in the nerve terminal and cell body sites induced by locally infused baclofen in the rat. Brain Res. 636, 111–114.
Yoshitake T., Reenila I., Ögren S. O., Hökfelt T., and Kehr J. (2003a) Galanin attenuates basal and antidepressant drug-induced increase of extracellular serotonin and noradrenaline levels in the rat hippocampus. Neurosci. Lett. 339, 239–242.
Yoshitake T., Wang F. H., Kuteeva E., et al. (2004) Enhanced hippocampal noradrenaline and serotonin release in galanin-overexpressing mice after repeated forced swimming test. Proc. Natl. Acad. Sci. USA 101, 354–359.
Yoshitake T., Yoshitake S., Yamaguchi M., Ögren S. O., and Kehr J. (2003b) Activation of 5-HT(1A) autoreceptors enhances the inhibitory effect of galanin on hippocampal 5-HT release in vivo. Neuropharmacology 44, 206–213.
Zachariou V., Brunzell D. H., Hawes J., et al. (2003) The neuropeptide galanin modulates behavioral and neurochemical signs of opiate withdrawal. Proc. Natl. Acad. Sci. USA 100, 9028–9033.
Zachariou V., Georgescu D., Kansal L., Merriam P., and Picciotto M. R. (2001) Galanin receptor 1 gene expression is regulated by cyclic AMP through a CREB-dependent mechanism. J. Neurochem. 76, 191–200.
Zhang X., Bean A. J., Wiesenfeld-Hallin Z., Xu X. J., and Hökfelt T. (1995a) Ultrastructural studies on peptides in the dorsal horn of the rat spinal cord—III. Effects of peripheral axotomy with special reference to galanin. Neuroscience 64, 893–915.
Zhang X., Ju G., Elde R., and Hökfelt T. (1993a) Effect of peripheral nerve cut on neuropeptides in dorsal root ganglia and the spinal cord of monkey with special reference to galanin. J. Neurocytol. 22, 342–381.
Zhang X., Nicholas A. P., and Hökfelt T. (1993b) Ultrastructural studies on peptides in the dorsal horn of the spinal cord—I. Co-existence of galanin with other peptides in primary afferents in normal rats. Neuroscience 57, 365–384.
Zhang X., Nicholas A. P., and Hökfelt T. (1995b) Ultrastructural studies on peptides in the dorsal horn of the rat spinal cord—II. Co-existence of galanin with other peptides in local neurons. Neuroscience 64, 875–891.
Zini S., Roisin M. P., Armengaud C., and Ben-Ari Y. (1993a) Effect of potassium channel modulators on the release of glutamate induced by ischaemic-like conditions in rat hippocampal slices. Neurosci. Lett. 153, 202–205.
Zini S., Roisin M. P., Langel Ü., Bartfai T., and Ben-Ari Y. (1993b) Galanin reduces release of endogenous excitatory amino acids in the rat hippocampus. Eur. J. Pharmacol. 245, 1–7.
Ögren S. O., Kehr J., and Schott P. A. (1996) Effects of ventral hippocampal galanin on spatial learning and on in vivo acetylcholine release in the rat. Neuroscience 75, 1127–1140.
Ögren S. O., and Pramanik A. (1991) Galanin stimulates acetylcholine release in the rat striatum. Neurosci. Lett. 128, 253–256.
Ögren S. O., Schott P. A., Kehr J., et al. (1998) Modulation of acetylcholine and serotonin transmission by galanin. Relationship to spatial and aversive learning. Ann. NY. Acad. Sci. 863, 342–363.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lundström, L., Elmquist, A., Bartfai, T. et al. Galanin and its receptors in neurological disorders. Neuromol Med 7, 157–180 (2005). https://doi.org/10.1385/NMM:7:1-2:157
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/NMM:7:1-2:157